Abstract
In order to study the mechanism of a novel vanillin derivative BVAN08, provide evidence and experimental data for developing it as a new potential anticancer drug. Hepatic cancer HepG2 cells and normal LO2 cells were used to investigate cytotoxicity of BVAN08. The MTT and colony-forming ability assays showed that BVAN08 significantly sensitized HepG2 cells to radiation rather than LO2 cells. Moreover, BVAN08 inhibited the growth of HepG2 cells in nude mice and exerted no effects on body weight and the number of the peripheral white blood cells. The immunohistochemistry results indicated that the DNA-PKcs expression the BVAN08 group tumor was lower than that of control group. BVAN08 obviously inhibits proliferation of HepG2 cells in vitro and in vivo supporting it as a promising anticancer drug candidate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
